Agenus Inc. (NASDAQ:AGEN - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.57 and traded as high as $6.33. Agenus shares last traded at $5.88, with a volume of 872,861 shares trading hands.
Analyst Ratings Changes
AGEN has been the topic of a number of research reports. Robert W. Baird increased their price objective on shares of Agenus from $4.00 to $6.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 4th. HC Wainwright upgraded shares of Agenus from a "neutral" rating to a "buy" rating and set a $25.00 target price on the stock in a research report on Wednesday, June 4th. B. Riley reiterated a "buy" rating on shares of Agenus in a research report on Monday, April 21st. Finally, Wall Street Zen upgraded shares of Agenus from a "strong sell" rating to a "hold" rating in a research report on Thursday, May 22nd.
Read Our Latest Stock Analysis on AGEN
Agenus Trading Up 0.3%
The company has a market cap of $161.78 million, a price-to-earnings ratio of -0.68 and a beta of 1.51. The company's 50 day moving average price is $5.20 and its 200 day moving average price is $3.58.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating analysts' consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. Sell-side analysts predict that Agenus Inc. will post -12.55 earnings per share for the current year.
Institutional Trading of Agenus
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Corton Capital Inc. acquired a new position in shares of Agenus in the 4th quarter valued at about $36,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Agenus in the 2nd quarter valued at about $85,000. Virtu Financial LLC acquired a new position in shares of Agenus in the 4th quarter valued at about $51,000. Apollon Wealth Management LLC increased its holdings in shares of Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 5,000 shares during the period. Finally, Bank of Montreal Can acquired a new position in shares of Agenus in the 4th quarter valued at about $69,000. Institutional investors and hedge funds own 61.46% of the company's stock.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Articles
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
